Compare XXII & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XXII | BBLG |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.2M |
| IPO Year | 2011 | 2014 |
| Metric | XXII | BBLG |
|---|---|---|
| Price | $1.49 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 129.3K | 75.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.96 | 45.13 |
| EPS | N/A | ★ N/A |
| Revenue | $25,832,530.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $370.28 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.43 |
| 52 Week High | $11.37 | $2.89 |
| Indicator | XXII | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 37.23 |
| Support Level | $1.67 | $0.43 |
| Resistance Level | $1.97 | $0.59 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 9.58 | 62.38 |
22nd Century Group Inc is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. The company manufactures and distributes the only combustible tobacco products containing minimally or non-addictive levels of nicotine. The Company has organized its business as a single reportable segment: tobacco, as it operates and derives all revenues from its tobacco operations and products.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.